PMN.TO Stock - ProMIS Neurosciences, Inc.
Unlock GoAI Insights for PMN.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | $8,138.696 | $1,401.393 | $920.177 | $348.744 |
| Gross Profit | N/A | $8,138.696 | $1,401.393 | $920.177 | $348.744 |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-23,379,912 | $-8,249,672.946 | $-4,440,534.521 | $-5,662,121.154 | $-7,464,630.001 |
| Net Income | $-12,578,075 | $-9,657,559.097 | $-4,440,534.521 | $-5,662,121.154 | $-7,464,630.001 |
| Net Margin | N/A | -118662.2% | -316865.8% | -615329.4% | -2140431.6% |
| EPS | $-1.68 | $-1.67 | $-0.93 | $-1.31 | $-1.87 |
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
PMN.TOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 13, 2024 | — | — | — | — |
Q1 2024 | Mar 6, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | — | — | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.27 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.58 | — | — |
Q1 2023 | Mar 8, 2023 | — | $-1.17 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-1.11 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.48 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.60 | — | — |
Q1 2022 | Mar 17, 2022 | — | $-0.42 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.13 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.05 | — | — |
Q2 2021 | May 14, 2021 | — | $-1.23 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.23 | — | — |
Q4 2020 | Nov 11, 2020 | $-0.60 | $-0.60 | 0.0% | = MET |
Q3 2020 | Aug 13, 2020 | $-0.60 | $-0.60 | 0.0% | = MET |
Q2 2020 | May 13, 2020 | — | $-0.27 | — | — |
Q1 2020 | Mar 18, 2020 | $-0.60 | $-0.60 | 0.0% | = MET |
Q4 2019 | Nov 14, 2019 | $-0.60 | $-0.60 | 0.0% | = MET |
Q3 2019 | Aug 13, 2019 | $-0.60 | $-0.60 | 0.0% | = MET |
Latest News
Frequently Asked Questions about PMN.TO
What is PMN.TO's current stock price?
What is the analyst price target for PMN.TO?
What sector is ProMIS Neurosciences, Inc. in?
What is PMN.TO's market cap?
Does PMN.TO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PMN.TO for comparison